Poor
Not Aligned
Patient Risk:
Medium
Summary
The AI-extracted claims largely contain OTC heartburn/acid indigestion, dosing/label-guidance, onset/comparative effectiveness, combination guidance, and action-oriented allergy guidance that are not supported by the provided FDA label excerpts. Only adverse reaction frequency items (headache/dizziness/constipation/diarrhea) are partially supported.
Category Scores
Accurate Statements
Common side effects of famotidine can include headache, dizziness, constipation or diarrhea, and nausea.
Headache (4.7%), dizziness (1.3%), constipation (1.2%), diarrhea (1.7%) are listed in ADVERSE REACTIONS; nausea is mentioned under ADVERSE REACTIONS (described as infrequent/other GI reactions).
Serious side effects from famotidine are less common but still possible.
ADVERSE REACTIONS lists rare/infrequent severe reactions (e.g., anaphylaxis/angioedema; toxic epidermal necrolysis; rare agranulocytosis/pancytopenia/leukopenia/thrombocytopenia).
Unsupported Statements
Famotidine is an H2 (histamine-2) blocker used to reduce stomach acid.
No provided label excerpt supports the mechanism statement.
OTC famotidine 20 mg is typically used for frequent heartburn (acid reflux symptoms).
No provided label excerpt supports OTC status or heartburn indication or dose strength (20 mg).
OTC famotidine 20 mg is typically used for acid indigestion/sour stomach.
No provided label excerpt supports OTC status or this indication framing.
OTC famotidine 20 mg is available without a prescription.
OTC availability is not present in the provided label excerpts.
OTC products usually provide dosing guidance on the label, including a maximum daily dose.
OTC labeling/dosing guidance (including maximum daily dose) is not present in the provided label excerpts.
You should follow package directions for timing and daily limits when taking OTC famotidine.
No label excerpt provides OTC package-direction instruction or timing/daily-limit language.
You should avoid taking more than the recommended amount of OTC famotidine.
No provided label excerpt supports this OTC-specific directive.
Famotidine is an acid reducer and typically works on stomach acid fairly soon after dosing.
No provided label excerpt supports onset/rapidity or acid-reducer description.
The exact onset of famotidine varies by person.
No provided label excerpt supports onset variability.
Antacids work faster but have a shorter duration than famotidine for symptom relief.
No provided label excerpt supports comparative statements vs antacids.
PPIs are stronger for prevention in many cases compared with famotidine.
No provided label excerpt supports comparative statements vs PPIs.
Famotidine can be combined with other OTC heartburn medicines depending on what else is taken.
No provided label excerpt supports combination/stacking guidance with other OTC heartburn medicines.
Many people can use an antacid for breakthrough symptoms while managing with famotidine.
No provided label excerpt supports breakthrough symptom rescue guidance.
Allergic reactions to famotidine may require stopping the drug and seeking urgent care.
No provided label excerpt provides action-oriented allergy management instructions.
For occasional heartburn, OTC H2 blockers can be enough.
No provided label excerpt supports OTC heartburn guidance.
For frequent symptoms (for example, occurring most days), many clinicians recommend a medical evaluation to confirm the cause and consider longer-term strategies.
No provided label excerpt supports clinician-recommendation phrasing or this counseling guidance.
Famotidine has been widely available for years.
No provided label excerpt supports availability history.
Many brands and generics of famotidine exist.
No provided label excerpt supports existence/number of brands or generics.
Contradictions
Important Omissions
FDA-label supported indications and limits from the provided label (e.g., short-term treatment of active duodenal ulcer; maintenance after healing; short-term treatment of active benign gastric ulcer; short-term treatment of GERD and esophagitis; pathological hypersecretory conditions), including study duration limits.
Importance:
High
Dose and administration details, including dosing duration limits and any specific dosing instructions (notably absent from provided label excerpts in DOSAGE AND ADMINISTRATION).
Importance:
High
Contraindications (provided label excerpt exists for hypersensitivity and cross-sensitivity to other H2 receptor antagonists, but none of the AI claims addressed contraindications).
Importance:
Moderate
Drug interactions section content (provided label excerpt indicates no drug interactions identified), but AI claims included combination guidance with other OTC heartburn medicines that was not label-supported.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Multiple claims are not label-supported, including OTC-specific dosing/direction adherence and combination/adjunct use guidance and action-oriented allergy care. However, no direct contradictions to the provided label excerpts were identified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
OTC heartburn/acid indigestion indications, OTC availability, OTC dosing/timing/max daily dose guidance, onset/comparative efficacy, combination with other OTC heartburn medicines, and allergy action advice are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or rephrase unsupported OTC/heartburn/onset/comparison/combination/allergy-action claims; align statements only with the provided label excerpts for indications (duodenal/benign gastric ulcer, GERD/esophagitis, pathological hypersecretory conditions) and the provided adverse reaction frequencies.